MAPT and early-onset autosomal dominant Alzheimer disease: In vivo, [18F]flortaucipir retention has been shown to correlate well with post mortem tau pathology in MAPT R406W mutation gene carriers [21] and to Alzheimer’s disease-related tau pathology [22].